Q-omics provides the consensus-scored HOXC12 profile across patient tissues and cancer cell-line models. HOXC12 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HOXC12 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HOXC12 RNA expression shows 8,183 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight ACC, KIRC, and SARC as cancer lineages where HOXC12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXC12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXC12 survival associations across molecular data types. HOXC12 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXC12 RNA expression–survival associations across cancer types. High HOXC12 expression shows unfavorable associations in ACC, MESO, CESC and LGG, but favorable associations in LAML and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HOXC12 RNA expression.
This table summarizes HOXC12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HOXC12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXC12 shows higher tumor expression in KIRC, BRCA, LUSC, STAD, LUAD and PRAD. The KIRC box plot shows higher HOXC12 RNA expression in tumor versus normal tissue (log2 FC = +0.173, t-test p < 0.001).
This table shows molecular features associated with HOXC12 in patient tissues and cancer cell lines. In patient samples, HOXC12 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXC12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
